The Oncology Biomarkers Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Oncology Biomarkers Market:
https://www.thebusinessresearchcompany.com/report/oncology-biomarkers-global-market-report
According to The Business Research Company’s Oncology Biomarkers Global Market Report 2024, The oncology biomarkers market size has grown rapidly in recent years. It will grow from $13.68 billion in 2023 to $15.69 billion in 2024 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to adoption in emerging economies, precision medicine initiatives, diagnostic innovations, drug development support, increased cancer incidence.
The oncology biomarkers market size is expected to see rapid growth in the next few years. It will grow to $26.09 billion in 2028 at a compound annual growth rate (CAGR) of 13.6%. The growth in the forecast period can be attributed to integration of next-generation sequencing (ngs), expansion of biomarker informatics, focus on predictive pharmacogenomics, rapid development of exosome-based biomarkers, adoption of spatial transcriptomics. Major trends in the forecast period include standardization and quality assurance, shift towards functional biomarkers, role of biomarkers in clinical trials, expanded applications in immunotherapy, real-time monitoring of treatment responses.
The rising incidence of cancer is expected to propel the growth of the oncology biomarker market going forward. Cancer is a disease in which some cells of the body grow uncontrollably and slowly spread to the rest of the body. Oncological biomarkers provide more information about the type of cancer by looking at the genes, proteins, and other substances in a person’s body. For instance, in February 2021, according to a report published by the American Cancer Society, a US-based voluntary health organization focused on cancer, an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths occurred in 2020. Further, in March 2023, according to the reports shared by the American Society of Clinical Oncology (ASCO)., a US-based professional organization, it was estimated that more than 12,000 people in the US were diagnosed with neuroendocrine tumors yearly. Further, approximately 171,000 people were living with this diagnosis in 2023. Therefore, the rising incidence of cancer will drive the oncology biomarker market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=12493&type=smp
The oncology biomarkers market covered in this report is segmented –
1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers
2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Other Profiling Technologies
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Ovarian Cancer, Liver Cancer, Other Cancer Types
4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications
5) By End-User: Hospitals, Academic And Cancer Research Institutes, Ambulatory Surgical Centers, Diagnostic Laboratories
Top Major Players
F Hoffmann-La Roche AG
Novartis AG
Thermo Fisher Scientific Inc.
Abbott Laboratories
Eli Lilly and Company
Adopting innovative and advanced technologies is a key trend in the oncology biomarker market. Major companies in the oncology biomarkers market are introducing new and innovative technologies to strengthen their position in the oncology biomarkers market. For instance, in 2022, OncoDNA, a Belgium-based company focused on precision medicine in oncology, launched OncoDEEP, a unique kit that enables laboratories to perform comprehensive biomarker testing. OncoDEEP uses Next-generation sequencing (NGS) technology and cloud-based software tools to provide laboratories with the ability to perform large-panel sequencing, obtain the molecular characterization of a tumor, analyze the raw data, and access extensive quality controls.
The oncology biomarkers market report table of contents includes:
1. Executive Summary
2. Oncology Biomarkers Market Characteristics
3. Oncology Biomarkers Market Trends And Strategies
4. Oncology Biomarkers Market – Macro Economic Scenario
5. Global Oncology Biomarkers Market Size and Growth
………………………..
32. Global Oncology Biomarkers Market Competitive Benchmarking
33. Global Oncology Biomarkers Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Oncology Biomarkers Market
35. Oncology Biomarkers Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
